{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:41:44Z","timestamp":1771328504479,"version":"3.50.1"},"reference-count":30,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s309763","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T21:37:46Z","timestamp":1622497066000},"page":"2375-2384","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0154-5777","authenticated-orcid":true,"given":"Sejung","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8273","authenticated-orcid":true,"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-3139","authenticated-orcid":true,"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-7225","authenticated-orcid":true,"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-9194","authenticated-orcid":true,"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/sm2.28","volume":"2","author":"Althof","year":"2014","journal-title":"Sex Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1743-6109.2007.00554.x","volume":"4","author":"Ahn","year":"2007","journal-title":"J Sex Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjp.0705800","volume":"142","author":"Ceglia","year":"2004","journal-title":"Br J Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.eururo.2006.05.055","volume":"50","author":"Giuliano","year":"2006","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"108608","DOI":"10.1016\/j.cbpc.2019.108608","volume":"226","author":"Demir","year":"2019","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"103244","DOI":"10.1016\/j.etap.2019.103244","volume":"72","author":"Ozaslan","year":"2019","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2174\/1574886309666140120095846","volume":"9","author":"F Lasker","year":"2014","journal-title":"Curr Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1743-6109.2009.01560.x","volume":"7","author":"McMahon","year":"2010","journal-title":"J Sex Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.eururo.2013.08.018","volume":"65","author":"Mirone","year":"2014","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.eururo.2009.01.025","volume":"55","author":"Buvat","year":"2009","journal-title":"Eur Urol"},{"key":"ref11","volume-title":"Premature Ejaculation","year":"2013"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1743-6109.2005.20112.x","volume":"2","author":"Waldinger","year":"2005","journal-title":"J Sex Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/pcc.v03n0105","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e13854","DOI":"10.1111\/and.13854","volume":"52","author":"Sahan","year":"2020","journal-title":"Andrologia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/iju.12256","volume":"21","author":"Kang","year":"2014","journal-title":"Int J Urol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2147\/DDDT.S126861","volume":"11","author":"Shin","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"ref18","unstructured":"Pharmacogene Variation Consortium. CYP3A4 allele nomenclature; Available from: https:\/\/www.pharmvar.org\/gene\/CYP3A4. Accessed May 11, 2021."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/00498250802617746","volume":"39","author":"Maekawa","year":"2009","journal-title":"Xenobiotica"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s12272-018-1075-6","volume":"41","author":"Byeon","year":"2018","journal-title":"Arch Pharm Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jcpt.12835","volume":"44","author":"Dorji","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1208\/s12248-020-00455-y","volume":"22","author":"Alhadab","year":"2020","journal-title":"AAPS J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1055\/s-2007-1002354","volume":"62","author":"Hiemke","year":"1994","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref25","volume":"7","author":"Uno","year":"2017","journal-title":"Neuropsychiatry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1177\/1060028013501994","volume":"47","author":"Funk","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref27","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide); 2017. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related. Accessed November 18, 2021."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/bcp.12681","volume":"80","author":"Maljuric","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.4088\/JCP.13r08672","volume":"75","author":"Beach","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"ref30","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) ver 5.0. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed November 18, 2021."}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=70046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=70046","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T21:37:54Z","timestamp":1622497074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/pharmacokinetics-tolerability-and-pharmacogenetics-of-da-8031-after-mu-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2147\/dddt.s309763","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}